In the last 12 months, insiders at Kairos Pharma, LTD. ($KAPA) filed 15 transactions with the SEC: 3 open-market purchases totaling $9,828 and 0 sales totaling $0. Net insider sentiment: net buying.
Kairos Pharma, LTD. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Yu John S (CEO and Chairman) — 3 transactions totaling $5,760
- Samuelson Doug (Chief Financial Officer) — 2 transactions totaling $3,750
- Murali Ramachandran (VP of Research and Development) — 3 transactions totaling $318
- Keyoung Hansoo Michael (Director) — 2 transactions totaling $0
- Bhowmick Neil (Chief Scientific Officer) — 2 transactions totaling $0
View all SEC Filings for Kairos Pharma, LTD. (KAPA).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct. 8, 2025 | Bhowmick Neil | Chief Scientific Officer | A | COMMON STOCK | 171756 | $0.00 | 1,311,739.0000 | 20,821,353 | 15.07% | 0.82% |
| Sept. 16, 2025 | Bae Hyun W. | Director | A | COMMON STOCK | 10000 | $0.00 | 54,286.0000 | 13,736,597 | 22.58% | 0.07% |
| Oct. 8, 2025 | Bae Hyun W. | Director | A | COMMON STOCK | 19084 | $0.00 | 73,370.0000 | 20,821,353 | 35.15% | 0.09% |
| Oct. 8, 2025 | Keyoung Hansoo Michael | Director | A | COMMON STOCK | 19084 | $0.00 | 29,084.0000 | 20,821,353 | 190.84% | 0.09% |
| Sept. 16, 2025 | Keyoung Hansoo Michael | Director | A | COMMON STOCK | 10000 | $0.00 | 10,000.0000 | 13,736,597 | 9999.99% | 0.07% |
| Oct. 8, 2025 | Singhvi Rahul | Director | A | COMMON STOCK | 19084 | $0.00 | 49,204.0000 | 20,821,353 | 63.36% | 0.09% |
| Oct. 8, 2025 | Samuelson Doug | Chief Financial Officer | A | COMMON STOCK | 152672 | $0.00 | 293,039.0000 | 20,821,353 | 108.77% | 0.73% |
| Oct. 8, 2025 | Yu John S | CEO and Chairman | A | COMMON STOCK | 190840 | $0.00 | 5,546,677.0000 | 20,821,353 | 3.56% | 0.92% |
| Oct. 8, 2025 | Murali Ramachandran | VP of Research and Development | A | COMMON STOCK | 152672 | $0.00 | 299,529.0000 | 20,821,353 | 103.96% | 0.73% |
| Jan. 1, 2025 | Bhowmick Neil | Chief Scientific Officer | A | COMMON STOCK | 14000 | $0.00 | 1,139,983.0000 | 13,736,597 | 1.24% | 0.10% |
| Jan. 1, 2025 | Yu John S | CEO and Chairman | A | COMMON STOCK | 14000 | $0.00 | 5,355,838.0000 | 13,736,597 | 0.26% | 0.10% |
| Jan. 1, 2025 | Murali Ramachandran | VP of Research and Development | A | COMMON STOCK | 14000 | $0.00 | 147,057.0000 | 13,736,597 | 10.52% | 0.10% |
| Nov. 25, 2024 | Murali Ramachandran | VP of Research and Development | P | COMMON STOCK | 200 | $1.59 | 133,057.0000 | 10,562,640 | 0.15% | 0.00% |
| Nov. 22, 2024 | Samuelson Doug | Chief Financial Officer | P | COMMON STOCK | 2500 | $1.50 | 60,796.0000 | 10,562,640 | 4.29% | 0.02% |
| Nov. 20, 2024 | Yu John S | CEO and Chairman | P | COMMON STOCK | 4000 | $1.44 | 5,341,837.0000 | 10,562,640 | 0.07% | 0.04% |